Loading...
XSTOLIDDS
Market cap645kUSD
Dec 23, Last price  
0.10SEK
1D
0.00%
1Q
-24.82%
Jan 2017
-98.31%
IPO
-98.94%
Name

Lidds AB

Chart & Performance

D1W1MN
XSTO:LIDDS chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
21.38%
Rev. gr., 5y
12.92%
Revenues
0k
-100.00%
0012,8797,6470001,028,5037,754,7080345,0003,554,0001,888,0000
Net income
-40m
L+8.36%
-1,875,302-3,482,198-3,712,308-3,889,997-7,063,673-7,815,219-6,634,079-6,669,276-3,747,681-23,833,063-32,342,000-37,270,000-37,103,000-40,206,000
CFO
-26m
L-26.33%
0-5,267,562-6,842,157-7,329,297-2,092,730-10,714,479-1,446,231-17,091,073-27,420,000-42,641,000-35,592,000-26,219,000
Earnings
Feb 20, 2025

Profile

LIDDS AB (publ), a pharmaceutical company, develops and sells pharmaceutical products for cancer and other diseases in Sweden. It is developing various drugs, such as NZ-2HOF to treat prostate cancer; NZ-DTX to treat breast, prostate, head, neck, stomach, and lung cancer; NZ-DOX for the treatment of solid tumors; NZ-IO, an immunotherapy; NZ-STING for the treatment of immuno-oncology; and NZ-TLR9 for enhancing cancer immunotherapies. LIDDS AB (publ) has a collaboration agreement with PharmIdea SIA to focus on anti-cancer drugs and sterile formulations. The company is based in Uppsala, Sweden.
URL
https://liddspharma.com/
IPO date
Jul 31, 2014
Employees
6
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,888
-46.88%
3,554
930.14%
Cost of revenue
12,922
61,217
70,888
Unusual Expense (Income)
NOPBT
(12,922)
(59,329)
(67,334)
NOPBT Margin
Operating Taxes
243
226
Tax Rate
NOPAT
(12,922)
(59,572)
(67,560)
Net income
(40,206)
8.36%
(37,103)
-0.45%
(37,270)
15.24%
Dividends
Dividend yield
Proceeds from repurchase of equity
42,239
3,697
45,169
BB yield
-616.34%
-5.89%
-13.73%
Debt
Debt current
3,994
Long-term debt
Deferred revenue
Other long-term liabilities
5,578
Net debt
(13,512)
(1,264)
(34,003)
Cash flow
Cash from operating activities
(26,219)
(35,592)
(42,641)
CAPEX
(282)
(811)
(2,402)
Cash from investing activities
(282)
(810)
(2,401)
Cash from financing activities
34,755
7,657
42,973
FCF
(11,897)
(59,288)
(67,911)
Balance
Cash
13,512
5,258
34,003
Long term investments
Excess cash
13,512
5,164
33,825
Stockholders' equity
(352,539)
(314,109)
(277,289)
Invested Capital
366,438
333,189
325,615
ROIC
ROCE
EV
Common stock shares outstanding
63,456
37,007
34,442
Price
0.11
-93.63%
1.70
-82.24%
9.55
-35.25%
Market cap
6,853
-89.08%
62,764
-80.92%
328,921
-22.87%
EV
(6,659)
61,500
294,918
EBITDA
(12,447)
(58,845)
(66,870)
EV/EBITDA
0.53
Interest
61
262
Interest/NOPBT